PROGNOSTIC VALUE OF PLACENTAL GROWTH FACTOR IN REDUCING THE FUNCTIONAL ACTIVITY OF A FORMING CHORION IN PREGNANT WOMEN WITH METABOLIC SYNDROME


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To establish a relationship of serum placental growth factor levels in the early gestational period (at 8—9 weeks) in pregnant women with metabolic syndrome (MS) to the clinical picture of preeclampsia and placental insufficiency (PI) and to placental morphological features. Subjects and methods. Eighty-nine pregnant women with MS (Group 1) were examined. A control group consisted of 25 healthy pregnant women (Group 2). Serum human placental grow factor levels (PlGF, pg/ml) were measured and placentas were morphologically studied in all the patients. Results. In the pregnant women with MS, the level of PlGF was ascertained to be slightly lower than that in the control group (р<0.01). The critical level of PlGF in the prognosis of development of PI is its value below 100 pg/ ml. A morphological study of placentas from the puerperas with metabolic syndrome suggests that placental immaturity is much more common with the low level of PlGF. Conclusion. The low level of PlGF may be used as a prognostic criterion for the development of PI and preeclampsia. The lower level of PlGF is in the f irst trimester of pregnancy, the earlier a package of measures should be launched to prevent severe gestational complications.

Texto integral

Acesso é fechado

Sobre autores

I. SAVELYEVA

Omsk State Medical Academy

Email: saveljeva_iv_omsk@mail.ru

V. KONEV

Omsk State Medical Academy

S. BARINOV

Omsk State Medical Academy

A. LETUCHIKH

Omsk State Medical Academy

A. LUBAVINA

Omsk State Medical Academy

Bibliografia

  1. Айламазян Э.К. и др., ред. Акушерство: Национальное руководство. М.: ГЭОТАР-Медиа; 2009: 445.
  2. Павлов К.А., Дубова Е.А., Щеголев А.И. Фетоплацентарный ангиогенез при нормальной беременности: роль плацентарного фактора роста и ангиопоэтинов. Акушерство и гинекология. 2010; 6: 10—5.
  3. Серов В.Н., Леуткина Г.С., Попова А.Д. Клинико-метаболическая картина у беременных с ожирением и дефицитом массы тела. Вестник Российской ассоциации акушеров-гинекологов. 2000; 4: 16—8.
  4. Стрижова Н.В., Сираканян И.К., Саркисова А.В., Гавриленкко А.С., Хлынова С.А. Особенности течения беременности, родов, послеродового и раннего неонатального периодов при метаболическом синдроме у женщин с ожирением. Акушерство и гинекология. 2004; 6: 22—4.
  5. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M. et al. Sinergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001; 7(5): 575—83.
  6. World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, Switzerland: WHO; 1999.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies